| 187.39 -3.45 (-1.81%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 234.52  |
1-year : | 245.03 |
| Resists | First : | 200.79 |
Second : | 209.78 |
| Pivot price | 194.58 |
|||
| Supports | First : | 186.22 |
Second : | 154.94 |
| MAs | MA(5) : | 189.94 |
MA(20) : | 194.18 |
| MA(100) : | 191.59  |
MA(250) : | 182.76 |
|
| MACD | MACD : | -2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 9 |
D(3) : | 11.6 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 212.57 | Low : | 162.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DGX ] has closed above bottom band by 14.4%. Bollinger Bands are 23% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 192.74 - 193.81 | 193.81 - 194.68 |
| Low: | 182.95 - 184.45 | 184.45 - 185.67 |
| Close: | 185.18 - 187.41 | 187.41 - 189.22 |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Fri, 08 May 2026
Quest Diagnostics (NYSE: DGX) sells $500M in 5.000% senior notes due 2036 - Stock Titan
Thu, 07 May 2026
How Quest Diagnostics Incorporated (DGX) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 07 May 2026
Quest Diagnostics Q1 2026 earnings preview - MSN
Thu, 07 May 2026
Quest Diagnostics: Updating Levels After Q1 Earnings (NYSE:DGX) - Seeking Alpha
Wed, 06 May 2026
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
Fri, 01 May 2026
[8-K] QUEST DIAGNOSTICS INC Reports Material Event - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 111 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 3,550 (K) |
| Shares Short P.Month | 3,870 (K) |
| EPS | 9.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 66.36 |
| Profit Margin | 9 % |
| Operating Margin | 14.1 % |
| Return on Assets (ttm) | 6.3 % |
| Return on Equity (ttm) | 14.5 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 33.87 |
| Sales Per Share | 101.89 |
| EBITDA (p.s.) | 20.14 |
| Qtrly Earnings Growth | 15.5 % |
| Operating Cash Flow | 1,850 (M) |
| Levered Free Cash Flow | 948 (M) |
| PE Ratio | 20.68 |
| PEG Ratio | 1.5 |
| Price to Book value | 2.82 |
| Price to Sales | 1.83 |
| Price to Cash Flow | 11.21 |
| Dividend | 0.86 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|